UnitedHealth Group’s stock declined by 35% in 2025 while the S&P 500 gained 16%, marking its worst annual performance in over a decade. The company’s medical care ratio jumped to 89.9% in the most recent quarter, compared with 82.3% two years earlier, reflecting sharply higher claim costs relative to premiums. This deterioration pushed operating margins down to their lowest levels since 2018. Investor confidence was further shaken when UnitedHealth missed its June earnings estimates, withdrew its guidance for the year and replaced its CEO, triggering the steep share sell-off.

After last year’s sell-off, UnitedHealth Group shares trade at roughly 18 times earnings, significantly below the five-year average multiple of 25. This valuation offers a 28% discount to long-term norms and supports the case for a margin of safety. In October, the company reported 12% year-over-year revenue growth and raised its full-year earnings outlook, now expecting adjusted EPS to range between $14.85 and $15.00. A dividend yielding 2.61%—more than double the S&P 500 average—adds to total return potential for patient investors.

UnitedHealth has launched a six-month Rural Payment Acceleration Pilot to cut Medicare Advantage payment collection times for rural hospitals from under 30 days to under 15 days, initially covering facilities in Oklahoma, Idaho, Minnesota and Missouri. Insights from this initiative will guide broader rollout plans to strengthen rural health systems. Meanwhile, a Senate Judiciary Committee report highlighted aggressive coding practices that inflated federal reimbursements beyond original program intent, and the Department of Justice is investigating the company’s billing strategies. Resolution of these inquiries will be a key catalyst for shares moving forward.